Failed clinical trials

A series of reviews focusing on the importance of learning from failed Alzheimers disease clinical trials and a number of measures that may accelerate drug development against the disease.

Investigational drugs for the treatment of AD: what can we learn from negative trials?

Given the level of interest and activity in the race to find a treatment for Alzheimer's disease, it is expected that a reasonably safe and effective drug will be identified within the next decade. It may be w...

Authors: Sandra A Jacobson and Marwan N Sabbagh

Citation: Alzheimer's Research & Therapy 2011 3:14

Content type: Review Published on: 15 April 2011
- View Full Text
- View PDF
Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials

Among the key challenges in Alzheimer's disease drug development is the timely completion of clinical trials. Unfortunately, clinical trials often suffer from slow or insufficient enrollment. Successful clinic...

Authors: Joshua D Grill and Jason Karlawish

Citation: Alzheimer's Research & Therapy 2010 2:34

Content type: Review Published on: 21 December 2010
- View Full Text
- View PDF
Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease

In a slowly progressive disorder like Alzheimer disease, evaluation of the clinical effect of novel drug candidates requires large numbers of patients and extended treatment periods. Current cell- and animal-b...

Authors: Henrik Zetterberg, Niklas Mattsson, Kaj Blennow and Bob Olsson

Citation: Alzheimer's Research & Therapy 2010 2:32

Content type: Review Published on: 30 November 2010
- View Full Text
- View PDF

Failed clinical trials

Investigational drugs for the treatment of AD: what can we learn from negative trials?

Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials

Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease